Novo Nordisk says CagriSema beat Lilly rival in diabetes trial
Novo Nordisk said CagriSema delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly’s rival drug.
4% in a late-stage trial in patients with diabetes, beating Eli Lilly's rival drug. The treatment has been viewed as a successor to Novo's weight-loss drug, Wegovy.